Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q3 2024 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Stephanie Lee - IR Matt Gline - CEO Conference Call Participants David Risinger - Leerink Partners Dennis Ding - Jefferies Yaron Werber - TD Cowen Brian Cheng - JPMorgan Yatin Suneja - Guggenheim Securities Douglas Tsao - H.C.
Roivant Sciences Tops Q3 Expectations
Biopharmaceutical company Roivant Sciences (ROIV 0.18%) reported earnings for the third quarter of 2024 on Monday, Feb. 10, that topped analysts' consensus estimates. Q3 revenue of $9.02 million surpassed estimates of $5 million, reflecting the company's strategic momentum.
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.24.
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed, trading flat while S&P 500 gained 19% since April. Brepocitinib shows promise for NIU treatment with Phase 2 success, but faces challenges including safety concerns and competition from Humira in the $1.5B market. Mosliciguat, targeting PH-ILD, could compete with Tyvaso ($433.8M in Q3 sales) through once-daily dosing and novel mechanism, pending Phase 2 results.
Roivant Sciences: A Biotech Growth Play With Major Ambitions
Roivant Sciences leverages its "Vant" model to develop and monetize drug candidates through subsidiaries, ensuring rapid advancement in therapeutic pipelines. Late-stage assets like Brepocitinib, IMVT-1402, and Mosliciguat position Roivant for significant clinical and commercial milestones by 2025. Strategic divestitures, like Dermavant's sale to Organon for $1.2 billion, support shareholder value through share buybacks and bolster financial stability.
Roivant's lung disease drug fails mid-stage trial
Roivant said on Tuesday its drug did not meet the main goal in a mid-stage trial evaluating it in patients with a type of lung disease.
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV ) Q2 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Stephanie Lee - Investor Relations Matt Gline - Chief Executive Officer Ben Zimmer - Chief Executive Officer, Priovant Conference Call Participants Louise Chen - Cantor Brian Cheng - JPMorgan Joyce Zhou - TD Cowen Andy Chen - Wolfe Research Douglas Tsao - H.C.
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.21.
Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Roivant's high valuation stems from its strong cash position, promising drug pipeline, Techbio assets, and strategic partnerships, making it a compelling buy. Recent sales of Telavant and Dermavant have bolstered Roivant's cash reserves. Key potential catalysts include Immunovant's batoclimab in Phase 3 trials and namilumab in a Phase 2 trial, though drug candidate performance remains a critical risk factor.
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Does Montes Archimedes Acquisition (ROIV) Have the Potential to Rally 35.12% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Montes Archimedes Acquisition (ROIV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21.
